Royce & Associates LP Buys 105,608 Shares of Enovis Corporation $ENOV

Royce & Associates LP raised its stake in shares of Enovis Corporation (NYSE:ENOV) by 14.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 826,848 shares of the company’s stock after purchasing an additional 105,608 shares during the quarter. Royce & Associates LP owned 1.45% of Enovis worth $22,027,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ENOV. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC increased its stake in Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Enovis in the third quarter valued at about $64,000. Danske Bank A S bought a new stake in Enovis in the third quarter valued at about $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the third quarter valued at about $80,000. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on ENOV shares. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Needham & Company LLC upped their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Insider Buying and Selling

In other news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the transaction, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought 5,000 shares of company stock valued at $121,983 in the last quarter. 2.90% of the stock is owned by insiders.

Enovis Price Performance

NYSE:ENOV opened at $24.31 on Wednesday. The firm has a market cap of $1.40 billion, a PE ratio of -1.22 and a beta of 1.41. Enovis Corporation has a 12 month low of $21.00 and a 12 month high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company’s 50-day moving average price is $24.05 and its two-hundred day moving average price is $25.18.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.